{
    "clinical_study": {
        "@rank": "75433", 
        "acronym": "TAPIT-1", 
        "arm_group": {
            "arm_group_label": "Treprostinil", 
            "arm_group_type": "Experimental", 
            "description": "Inhaled prostanoid therapy with Treprostinil"
        }, 
        "brief_summary": {
            "textblock": "An Open Label, Pilot Study Testing the Safety and Efficacy of Inhaled Treprostinil (Tyvaso\u00ae)\n      in the Treatment of Pulmonary Hypertension (PH) Associated with Chronic Obstructive\n      Pulmonary Disease (COPD)"
        }, 
        "brief_title": "Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pulmonary Hypertension", 
            "COPD"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Pulmonary Disease, Chronic Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a pilot study of 10 patients that have COPD-PH. Primary outcome measure is to see if\n      this drug is safe for this patient population and the secondary measure is to see if the\n      drug improves patient functional capacity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: must have:\n\n          -  be between the ages of 30 and 80\n\n          -  have a clinical diagnosis of Gold stage 2 to 4 COPD\n\n          -  have a diagnosis of pulmonary hypertension established by a historic  right heart\n             catheterization\n\n          -  a minimum weight of 45 Kg\n\n          -  minimum systolic blood pressure of >90 mmHg\n\n          -  be able to perform a six minute walk test\n\n          -  be able to maintain a oxygen saturation >88% at rest (with or without oxygen)\n\n          -  be treated with background therapy for COPD for a minimum of 1 month prior to\n             consideration of enrollment.\n\n          -  be competent to understand the information given in the Institutional Review Board\n             (IRB) or Independent Ethics Committee (IEC) approved Informed Consent Form and must\n             sign the form prior to the initiation of any study procedure.\n\n        Exclusion Criteria. Cannot have or be:\n\n          -  The presence of pulmonary venous hypertension defined by a historical right heart\n             catheterization\n\n          -  Gold Stage I COPD\n\n          -  documented left ventricular dysfunction as measured by echocardiography\n\n          -  pregnant or breastfeeding\n\n          -  Recipient of a lung transplant\n\n          -  received chronic prostanoid therapy for pulmonary hypertension within 4 weeks prior\n             to the screening appointment\n\n          -  A requirement of greater than 9 l/min of O2 to maintain oxygen saturations greater\n             than 88% at rest\n\n          -  No other serious medical conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758744", 
            "org_study_id": "12-0560"
        }, 
        "intervention": {
            "arm_group_label": "Treprostinil", 
            "description": "Treprostinil: Inhaled prostanoid therapy", 
            "intervention_name": "Inhaled Treprostinil Therapy", 
            "intervention_type": "Drug", 
            "other_name": "Tyvaso \u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Treprostinil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "COPD PH", 
            "COPD associated Pulmonary Hypertension", 
            "COPD and Pulmonary Hypertension", 
            "Disease"
        ], 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "contact": {
                "email": "cheryl.abbott@ucdenver.edu", 
                "last_name": "Cheri Abbott, RN", 
                "phone": "303-724-7466"
            }, 
            "facility": {
                "address": {
                    "city": "Aurora", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80045"
                }, 
                "name": "University of Colorado Denver"
            }, 
            "investigator": {
                "last_name": "Todd M. Bull, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "TAPIT-1: Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1", 
        "overall_contact": {
            "email": "cheryl.abbott@ucdenver.edu", 
            "last_name": "Cheri Abbott, RN", 
            "phone": "303-724-7466"
        }, 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Todd M. Bull, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A 4-Week, Open Label Study Testing the Safety of Inhaled Treprostinil (Tyvaso\u00ae) in the Treatment of Pulmonary Hypertension (PH) Associated with Chronic Obstructive Lung Disease (COPD) (PH-COPD)", 
            "measure": "To assess the safety of Tyvaso \u00ae as assessed by changes or stability of acute oxygenation (pulse oximetry) and spirometry (FEV1).", 
            "safety_issue": "Yes", 
            "time_frame": "This is a 4 week trial"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758744"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A change in functional class is assessed as improvement or deterioration in the patient's functional status", 
                "measure": "New York Heart Association (NYHA) functional class", 
                "safety_issue": "Yes", 
                "time_frame": "Change in New York Heart Association (NYHA) functional class assessed at baseline and at week 4."
            }, 
            {
                "description": "A change in how far the subject can walk in 6 minutes will be measured at baseline and compared to how far the subject can walk in 6 minutes at week 4.", 
                "measure": "Six minute walk distance", 
                "safety_issue": "Yes", 
                "time_frame": "Change from baseline in 6 minute walk distance at 4 weeks"
            }, 
            {
                "description": "Clinical worsening is described as Death, hospitalization (all cause)and COPD exacerbations (worsening of respiratory symptoms which require treatment with oral corticosteroids, antibiotics or both).", 
                "measure": "Clinical Worsening", 
                "safety_issue": "Yes", 
                "time_frame": "From the time of randomization to until the subject discontinues from study for any cause, assessed up to 4 weeks"
            }, 
            {
                "description": "The phagocytic index is the average number of bacteria ingested per phagocyte in an incubated mixture of bacteria, phagocytes, and blood serum. We will also be looking a a change in gene expression of these (PBMC) cells.\n------------------------------------------------------------------------------", 
                "measure": "Peripheral Blood Mononuclear Cells (PBMC) phagocytic index (PI) and PBMC gene expression", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in PBMC PI and PBMC gene expression at 4 weeks"
            }, 
            {
                "description": "The St. George's questionnaire is a quality of life questionnaire completed by the subject at baseline and at week 4.", 
                "measure": "St. George's Chronic Obstructive Pulmonary Disease (COPD) questionnaire", 
                "safety_issue": "No", 
                "time_frame": "change from baseline in the St. George's respiratory questionnaire at 4 weeks"
            }
        ], 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}